Ananda Scientific Partners with Benta to Advance PTSD Treatment Development in Europe and MENA
核心洞察
Ananda Scientific and Benta SAS (搜索) signed a Memorandum of Understanding to explore collaboration on developing PTSD (搜索) treatments for Europe and the Middle East/North Africa region.
The partnership focuses on Ananda's investigational drug Nantheia (搜索)™, currently in clinical trials for PTSD (搜索) treatment, addressing a critical unmet medical need with no new approved PTSD drugs in over two decades.
Under the agreement, Ananda will lead clinical development while Benta will provide manufacturing expertise and infrastructure for potential future product scale-up and regional distribution.
Ananda Scientific Inc (搜索)., a clinical-stage drug development company, has signed a Memorandum of Understanding (MOU) with France-based Benta SAS (搜索) to explore collaboration on advancing Post-Traumatic Stress Disorder (搜索) (PTSD (搜索)) treatments in Europe and the Middle East/North Africa (MENA) region. The partnership centers on Ananda's investigational drug Nantheia (搜索)™, currently undergoing clinical trials for PTSD treatment.
Addressing Critical Unmet Medical Need
PTSD (搜索) represents a significant global health challenge, affecting millions of people worldwide as a chronic and debilitating neuropsychiatric condition. The disorder's devastating impact extends beyond patients to families and communities, yet the therapeutic landscape remains stagnant. According to the companies, no new drug for PTSD has received approval in over two decades, highlighting a critical unmet medical need in mental health care.
Strategic Collaboration Framework
Under the MOU terms, Ananda Scientific will maintain leadership over all clinical development aspects of Nantheia (搜索)™, while Benta will contribute its manufacturing expertise and infrastructure capabilities. This division of responsibilities positions Benta to support potential future product development, scale-up operations, and regional distribution across Europe and the MENA region.
"This MOU represents an important step in our mission to deliver innovative therapies for neuropsychiatric disorders (搜索) where patients have limited treatment options," said Sohail Zaidi, Chief Executive Officer of Ananda Scientific Inc (搜索). "There is an urgent and growing global need for new therapies for PTSD (搜索). With our Nantheia (搜索)™ clinical development program, we are advancing a promising candidate through rigorous clinical evaluation, and potential collaborations such as this can help ensure readiness for future manufacturing and distribution."
Manufacturing and Distribution Strategy
Benta SAS (搜索) brings established pharmaceutical manufacturing and distribution capabilities to the partnership, with particular expertise in the European and MENA markets. The company's involvement aims to ensure manufacturing readiness and regional access for Ananda's PTSD (搜索) treatment candidate.
"At Benta, we are committed to supporting the advancement of transformative therapeutics that can have a real impact on patients' lives," said Bernard Tannoury, President of Benta SAS (搜索) (France). "We are pleased to explore opportunities to contribute our manufacturing capabilities and technical expertise to support Ananda Scientific's efforts in bringing innovative PTSD (搜索) treatments to patients in Europe and the MENA region."
Clinical Development Pipeline
Ananda Scientific's lead investigational program, Nantheia (搜索)™, is currently being evaluated in clinical trials for PTSD (搜索) and other neuropsychiatric indications. The company leverages advanced drug delivery technology as part of its clinical pipeline approach, focusing on addressing major unmet medical needs through rigorous clinical research and global partnerships.
The collaboration reflects both companies' commitment to advancing mental health care through scientific innovation and high-quality pharmaceutical development, with the ultimate goal of improving outcomes for patients affected by PTSD (搜索) worldwide.